Factors influencing warfarin dose requirements in African-Americans (Q46885448)

26 December 2017

title

Factors influencing warfarin dose requirements in African-Americans (English)

1 reference

26 December 2017

1 reference

Kathryn M Momary

1

1 reference

26 December 2017

Nancy L Shapiro

2

1 reference

26 December 2017

Marlos Ag Viana

3

1 reference

26 December 2017

Edith A Nutescu

4

1 reference

26 December 2017

Cathy M Helgason

5

1 reference

26 December 2017

Larisa H Cavallari

6

1 reference

26 December 2017

publication date

1 November 2007

1 reference

26 December 2017

published in

Pharmacogenomics

1 reference

26 December 2017

volume

8

1 reference

26 December 2017

issue

11

1 reference

26 December 2017

page(s)

1535-1544

1 reference

26 December 2017

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Patient-specific factors predictive of warfarin dosage requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Interindividual variability in sensitivity to warfarin--Nature or nurture?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Evaluation of genetic factors for warfarin dose prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

A physiological threshold for protection against menadione toxicity by human NAD(P)H:quinone oxidoreductase (NQO1) in Chinese hamster ovary (CHO) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Development of a self-assessment instrument to determine daily intake and variability of dietary vitamin K.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Population variation in VKORC1 haplotype structure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Population pharmacokinetics of racemic warfarin in adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Pharmacogenetics of acenocoumarol pharmacodynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Association of warfarin dose with genes involved in its action and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Purified vitamin K epoxide reductase alone is sufficient for conversion of vitamin K epoxide to vitamin K and vitamin K to vitamin KH2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Warfarin dose related to apolipoprotein E (APOE) genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

APOE genotype makes a small contribution to warfarin dose requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1535

10.2217/14622416.8.11.1535

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017